Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma Inc (EVOK) is a biotechnology innovator focused on advancing treatments for gastrointestinal disorders, notably through its FDA-approved GIMOTI® nasal spray for diabetic gastroparesis. This page provides investors and healthcare professionals with essential updates on the company's strategic initiatives, clinical developments, and market progress.
Access real-time announcements including regulatory milestones, financial results, and partnership agreements that shape Evoke's position in specialty pharmaceuticals. Our curated news feed covers critical updates such as prescription adoption trends, distribution network expansions, and intellectual property developments related to nasal drug delivery technologies.
Key areas of coverage include GIMOTI commercialization progress, pharmacy network partnerships, and operational efficiency initiatives. Bookmark this page to stay informed about Evoke Pharma's advancements in addressing unmet needs in gastrointestinal care through its non-oral therapeutic solutions.
Evoke Pharma reported a strong first quarter for 2024, with net product sales increasing by 114% year-over-year to $1.7 million. The company saw a 70% growth in prescriber numbers compared to Q4 2023 and reaffirmed its $14 million net revenue guidance for 2024. Challenges included a cyberattack and increased co-pay expenses, but the company remains optimistic, leveraging its partnership with ASPN Pharmacies. The first quarter also saw the company raising $8.8 million through a public offering. Net loss was reduced to $1.6 million from $2.2 million in Q1 2023. Cash position stands at $9.7 million, expected to fund operations into Q1 2025.
FAQ
What is the current stock price of Evoke Pharma (EVOK)?
What is the market cap of Evoke Pharma (EVOK)?
